The Biden administration says Medicare recipients will save about $1.5 billion on out-of-pocket costs for medications to treat diabetes, heart disease, types of arthritis and other ailments under new prices negotiated with drug companies that will take effect in 2026.

The savings range from 79% for Januvia, used to manage diabetes, to 38% for Imbruvica, which is used to treat blood cancers. That is the medication’s cost before any discounts or rebates are applied, but not what the price people actually pay when filling their prescriptions.

A look at the drugs and the negotiated prices.

Manufacturer: Merck Sharp Dohme

Negotiated price: $113 for a 30-day supply

Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill:

Negotiated price: $119 for a 30- day supply

Conditions: Diabetes, heart failure and chronic kidney disease

Negotiated price: $178.50 for a 30-day supply

Conditions: Rheumatoid arthritis, psoriasis and psoriatic arthritis

Negotiated price: $2,355 for a 30-day supply

Manufacturer: Boehringer Ingelheim

Conditions: Diabetes, heart failure and chronic kidney disease

Negotiated price: $197 for a 30-day supply

Manufacturer: Janssen Biotech Inc.

Conditions: Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis

Negotiated price: $4,695 for a 30-day supply

Conditions: Prevention and treatment of blood clots. Reduction of risk for patients with coronary or peripheral artery disease

Negotiated price: $197 for a 30-day supply

Manufacturer: Bristol Myers Squibb

Conditions: Prevention and treatment of blood clots

Negotiated price: $231 for a 30-day supply

Manufacturer: Novartis Pharms Corp

Negotiated price: $295 for a 30-day supply

Manufacturer: Pharmacyclics LLC

Negotiated price: $9,319 for a 30-day supply